Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Michael E. Nassif,Sheryl L. Windsor,Fengming Tang,Yevgeniy Khariton,Mansoor Husain,Silvio E. Inzucchi,Darren K. McGuire,Bertram Pitt,Benjamin M. Scirica,Bethany A. Austin,Mark H. Drazner,Michael Fong,Michael M. Givertz,Robert J. Gordon,Rita Jermyn,Stuart D. Katz,Sumant Lamba,David E. Lanfear,Shane J. LaRue,JoAnn Lindenfeld,Michael Malone,Kenneth B. Margulies,Robert J. Mentz,R. Kannan Mutharasan,Michael Pursley,Guillermo E. Umpierrez,Mikhail Kosiborod

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

2019

Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few ...

Keywords:

Dapagliflozin
Heart failure
Diabetes mellitus
Biomarker (medicine)
Cardiology
Internal medicine
Ejection fraction
Medicine

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations